文献速递胃肠动力与功能性疾病

粪菌移植可减轻部分以腹胀为主的肠易激综合征患者症状:安慰剂对照随机试验的短期与长期结果

Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
PubMed 文献 · Gastroenterology · 2020-07-15

这项双盲随机安慰剂对照试验纳入难治性肠易激综合征患者,供体粪菌经鼻空肠单次给药(n=43)对比自体粪菌(n=19),随访1年。第12周供体粪菌组56%患者主要终点均改善,安慰剂组为26%(P=0.03);疗效随1年下降,再次粪菌移植可恢复既往应答者的应答。

要点

  • 第12周供体粪菌组56%患者主要终点均改善,安慰剂组为26%(P=0.03)。
  • 供体粪菌组女性应答比例69%高于男性29%(P=0.01)。
  • 单次粪菌移植后效应持续超过1年者供体粪菌组21%,安慰剂组5%。

核心结论

  • 在难治性以腹胀为主的肠易激综合征患者中,粪菌移植较安慰剂(自体粪菌移植)减轻症状,但效应在1年内减弱。
  • 再次粪菌移植可恢复既往对供体粪菌有应答者的应答,但对既往无应答者无效。
  • 应答与粪菌移植前粪便微生物组组成相关,或可作为选择患者的生物标志物。

研究设计与样本

  • 双盲、安慰剂对照随机试验,2015年12月至2017年10月实施,随访1年。
  • 难治性肠易激综合征定义为≥3种常规治疗失败,随机接受单次鼻空肠供体粪菌(n=43)或自体粪菌(n=19)。
  • 主要终点为第12周肠易激综合征症状与腹胀改善(应答);次要终点为症状评分与生活质量变化。
  • 采集粪便行微生物组扩增子测序;试验后提供开放标签再次移植。

主要发现

  • 第12周供体粪菌组56%患者两个主要终点均改善,安慰剂组为26%(P=0.03)。
  • 供体粪菌组不适感平均降低19%(移植前中位评分3.98,范围2.13-6.00;移植后中位评分3.1,范围951.29-5.90,原文此处范围下限写作951.29)。
  • 供体粪菌组排便频率平均降低13%(移植前中位评分2.10,范围0.57-14.29;移植后中位评分1.7,范围0.71-4.29),便急平均降低38%(移植前中位评分0.61,范围0.00-1.00;移植后中位评分0.37,范围0.00-1.00)。
  • 供体粪菌组腹痛平均降低26%(移植前中位评分3.88,范围1.57-5.17;移植后中位评分2.80,范围1.14-4.94),排气平均降低10%(移植前中位评分3.42,范围0.71-6.00;移植后中位评分3.07,范围0.79-4.23)。
  • 供体粪菌组生活质量平均提高16%(移植前中位评分32.6,范围11-119;移植后中位评分43.1,范围32.25-99);女性应答比例69%高于男性29%(P=0.01)。

关键数值与推荐

  • 应答者粪菌移植前粪便微生物组多样性高于无应答者(P=0.04),基线组成不同(P=0.04),但无特定标记菌群与应答相关。
  • 单次粪菌移植后效应持续超过1年者供体粪菌组21%,安慰剂组5%。
  • 再次粪菌移植使67%初始对供体粪菌有应答者症状减轻,对既往无应答者无效。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder associated with intestinal dysbiosis. Given the reported promising results of open-label fecal microbiota transplantation (FMT) therapy in patients with predominant abdominal bloating, we studied efficacy of this treatment in a randomized, placebo-controlled trial. METHODS: Patients with refractory IBS, defined as failure of ≥3 conventional therapies, were randomly assigned to single-dose nasojejunal administration of donor stools (n = 43) or autologous stools (n = 19) in a double-blind study, performed from December 2015 through October 2017, and were followed up for 1 year. IBS-related symptoms were assessed by using a daily symptom diary to determine general abdominal discomfort, abdominal bloating, abdominal pain, and flatulence on a scale of 1-6. Number of daily bowel movements, consistency of the stools, and abdominal circumference were also recorded. Patients completed the IBS-specific quality of life questionnaire. Primary endpoints were improvement of IBS symptoms and bloating at 12 weeks (response). Secondary endpoints were changes in IBS symptom scores and quality of life. Stool samples were collected for microbiota amplicon sequencing. Open-label retransplantation was offered after the trial. RESULTS: At week 12, 56% of patients given donor stool reported improvement in both primary endpoints compared with 26% of patients given placebo (P = .03). Patients given donor stool had significant improvements in level of discomfort (mean reduction, 19%; median score before FMT, 3.98; range, 2.13-6.00; median score after FMT, 3.1; range, 951.29-5.90), stool frequency (mean reduction, 13%; median score before FMT, 2.10; range, 0.57-14.29; median score after FMT 1.7; range, 0.71-4.29), urgency (mean reduction, 38%; median score before FMT, 0.61; range, 0.00-1.00; median score after FMT, 0.37; range, 0.00-1.00), abdominal pain (mean reduction, 26%; median score before FMT, 3.88; range, 1.57-5.17; median score after FMT, 2.80; range, 1.14-4.94), flatulence (mean reduction, 10%; median score before FMT, 3.42; range, 0.71-6.00; median score after FMT, 3.07; range, 0.79-4.23), and quality of life (mean increase, 16%; median score before FMT 32.6; range, 11-119; median score after FMT, 43.1; range, 32.25-99). A significantly higher proportion of women given donor stool (69%) had a response than men (29%) (P = .01). Fecal samples from responders had higher diversity of microbiomes before administration of donor material than fecal samples from nonresponders (P = .04) and distinct baseline composition (P = .04), but no specific marker taxa were associated with response. After single FMT, 21% of patients given donor stool reported effects that lasted for longer than 1 year compared with 5% of patients given placebo stool. A second FMT reduced symptoms in 67% of patients with an initial response to donor stool but not in patients with a prior nonresponse. CONCLUSIONS: In a randomized trial of patients with treatment-refractory IBS with predominant bloating, FMT relieved symptoms compared with placebo (autologous transplant), although the effects decreased over 1 year. A second FMT restored the response patients with a prior response. Response was associated with composition of the fecal microbiomes before FMT; this might be used to as a biomarker to select patients for this treatment. ClinicalTrials.gov, Number: NCT02299973.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Holvoet T, Joossens M, Vázquez-Castellanos JF, et al. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Gastroenterology. 2020. PMID: 32681922. doi:10.1053/j.gastro.2020.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。